logo
logo

Tvardi’s TTI-101 Receives $5 Million in Grant Funding to Support Clinical Trials and Translational Research

Jul 24, 2020•almost 5 years ago

Description

Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of Tvardi’s lead compound, TTI-101. The three National Cancer Institute (NCI) funding awards are two Specialized Programs of Research Excellence (SPORE) grants to support clinical trials of TTI-101 in hepatocellular carcinoma (HCC) and gastrointestinal cancer as well as funding from the PREVENT program to support translational work of TTI-101 in HCC prevention.

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Related People